Personalized Medicine Debate, 15 October 2019: Pharmacogenetics; reality or dream?

On behalf of the program leaders of de APH program Personalized Medicine we would like to invite you to the first event in the Personalized Medicine Debate Series:

Pharmacogenetics; reality or dream?

Effective implementation of pharmacogenetic guidelines, clinical utility of genotyping vs phenotyping at the enzyme level, the cost-effectiveness of such approaches, and the innovative application of a pre-emptive pharmacogenomics panel are subjects of study within the APH-Personalized Medicine program.

With these approaches there are many values at strike. Time for a debate with experts.

Mark your calendar. More detailed info will follow soon.

Please click here to register and stay updated.

(Circa 50 seats available!)

------------------------------------------------------------------------------------------------------------------------------------------------------------------

Background:

In September 2017 the national guideline for colorectal carcinoma was updated to recommend DPD genotyping before treatment with fluoropyrimidines. This is an example of personalized medicine as a result of the developments in the field of Pharmacogenetics.

Effective implementation of pharmacogenetic guidelines, clinical utility of genotyping vs phenotyping at the enzyme level, the cost-effectiveness of such approaches, and the innovative application of a pre-emptive pharmacogenomics panel are subjects of study within the APH-Personalized Medicine program.

With this debate, we hope to evaluate and stimulate responsible implementation of pharmacogenomics, as well as other personalized medicine approaches, in light of our proposed value-based healthcare framework. We hope to discuss the relevance of (transparency about) the different values at stake when evaluating personalised medicine application.(see white paper)